Publication Name	World Journal of Gastroenterology
Manuscript ID	45008
Country	Japan

Received	2018-12-07 06:01
Peer-Review Started	2018-12-08 14:19
To Make the First Decision	2018-12-29 00:54
Return for Revision	2018-12-29 04:00
Revised	2019-01-10 00:16
Second Decision	2019-01-14 09:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2019-01-15 01:35
Articles in Press	2019-01-15 01:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-20 10:24
Publish the Manuscript Online	2019-02-21 09:31

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Manuscript Source	Unsolicited Manuscript
All Author List	Masatoshi Kudo
ORCID	Author(s) ORCID Number Masatoshi Kudo http://orcid.org/0000-0002-4102-3474
Funding Agency and Grant Number
Corresponding Author	Masatoshi Kudo, MD, PhD, Director, Director, Full Professor, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka 589-8511, Japan. m-kudo@med.kindai.ac.jp
Key Words	Hepatocellular carcinoma; Molecular targeted agent; Immune checkpoint inhibitor; Sorafenib; Lenvatinib
Core Tip	Systemic therapy for hepatocellular carcinoma (HCC) has markedly advanced since sorafenib was approved in 2007. Since then, there was no active drug for 10 years that prolong overall survival, however, in 2017 and 2018, clinical trials of 4 more molecular targeted agents including lenvatinib as first line agent, regorafenib, cabozantinib and ramucirumab as second line agent have shown their survival benefit. In addition, immune check point inhibitors, nivolumab and pembrolizumab, were approved by Food and Drug Administration. Combination cancer immunotherapy, that combines immune checkpoint inhibitors and molecular targeted agents show great promise in the treatment of HCC.
Publish Date	2019-02-21 09:31
Citation	Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
URL	https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
DOI	https://dx.doi.org/10.3748/wjg.v25.i7.789

Full Article (PDF)	WJG-25-789.pdf
Full Article (Word)	WJG-25-789.docx
Manuscript File	45008-Review.docx
Answering Reviewers	45008-Answering reviewers.pdf
Audio Core Tip	45008-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	45008-Conflict-of-interest statement.pdf
Copyright License Agreement	45008-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	45008-Language certificate.pdf
Peer-review Report	45008-Peer-review(s).pdf
Scientific Misconduct Check	45008-Scientific misconduct check.pdf
Scientific Editor Work List	45008-Scientific editor work list.pdf